{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:04:27Z","timestamp":1785600267367,"version":"3.56.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"crossref","award":["100009945"],"award-info":[{"award-number":["100009945"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tissue fibrosis underlies the majority of human mortality to date with close to half of all reported deaths having a fibrotic etiology. The progression of fibrosis is very complex and reputed irreversible once established. Although some preventive options are being reported, therapeutic options are still scarce and in very high demand, given the rise of diseases linked to fibroproliferative disorders. Our work explored four platforms, complementarily, in order to screen preventive and therapeutic potentials of the antiparasitic drug Praziquantel as a possible antifibrotic. We applied the mouse CCl<jats:sub>4<\/jats:sub>-driven liver fibrosis model, the mouse chronic schistosomiasis liver fibrosis model, as well as novel 2D and 3D human cell-based co-culture of human hepatocytes, KCs (Kupffer cells), LECs (Liver Endothelial Cells), HSCs (Hepatic Stellate Cells) and\/or myofibroblasts to mimic in vivo fibrotic responses and dynamics. Praziquantel showed some effect on fibrosis marker when preventively administered before severe establishment of fibrosis. However, it failed to potently reverse already established fibrosis. Together, we provided a novel sophisticated multi-assay screening platform to test preventive and therapeutic antifibrotic candidates. We further demonstrated a direct preventive potential of Praziquantel against the onset of fibrosis and the confirmation of its lack of therapeutic potential in reversing already established fibrosis.<\/jats:p>","DOI":"10.1038\/s41598-020-67514-4","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T10:03:57Z","timestamp":1593511437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models"],"prefix":"10.1038","volume":"10","author":[{"given":"Justin Komguep","family":"Nono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thabo","family":"Mpotje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgianna","family":"Varrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada Abdel","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paballo","family":"Mosala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lerato","family":"Hlaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin Donald","family":"Kamdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Brombacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"67514_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3947\/ic.2013.45.1.32","volume":"45","author":"JY Chai","year":"2013","unstructured":"Chai, J. Y. Praziquantel treatment in trematode and cestode infections: an update. Infect. Chemother. 45, 32\u201343 (2013).","journal-title":"Infect. Chemother."},{"key":"67514_CR2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00389899","volume":"52","author":"R Gonnert","year":"1977","unstructured":"Gonnert, R. & Andrews, P. Praziquantel, a new board-spectrum antischistosomal agent. Z. Parasitenkd. 52, 129\u2013150 (1977).","journal-title":"Z. Parasitenkd."},{"key":"67514_CR3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/infdis\/159.3.589","volume":"159","author":"SH Xiao","year":"1989","unstructured":"Xiao, S. H. & Catto, B. A. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J. Infect. Dis. 159, 589\u2013592 (1989).","journal-title":"J. Infect. Dis."},{"key":"67514_CR4","doi-asserted-by":"crossref","first-page":"18873","DOI":"10.1074\/jbc.AC119.011093","volume":"294","author":"SK Park","year":"2019","unstructured":"Park, S. K. et al. The anthelmintic drug praziquantel activates a schistosome transient receptor potential channel. J. Biol. Chem. 294, 18873\u201318880 (2019).","journal-title":"J. Biol. Chem."},{"key":"67514_CR5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2174\/1568026618666181029143214","volume":"18","author":"CM Thomas","year":"2018","unstructured":"Thomas, C. M. & Timson, D. J. The mechanism of action of praziquantel: six hypotheses. Curr. Top. Med. Chem.18, 1575\u20131584 (2018)","journal-title":"Curr. Top. Med. Chem."},{"key":"67514_CR6","doi-asserted-by":"crossref","first-page":"e02582","DOI":"10.1128\/AAC.02582-16","volume":"61","author":"N Vale","year":"2017","unstructured":"Vale, N. et al. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob. Agents Chemother. 61, e02582\u201316 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67514_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S0022149X08960776","volume":"82","author":"S Velebny","year":"2008","unstructured":"Velebny, S., Hrckova, G. & Kogan, G. Impact of treatment with praziquantel, silymarin and\/or beta-glucan on pathophysiological markers of liver damage and fibrosis in mice infected with Mesocestoides vogae (Cestoda) tetrathyridia. J. Helminthol. 82, 211\u2013219 (2008).","journal-title":"J. Helminthol."},{"key":"67514_CR8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1017\/S0031182005009364","volume":"132","author":"G Hrckova","year":"2006","unstructured":"Hrckova, G., Velebny, S., Daxnerova, Z. & Solar, P. Praziquantel and liposomized glucan-treatment modulated liver fibrogenesis and mastocytosis in mice infected with Mesocestoides vogae (M. corti, Cestoda) tetrathyridia. Parasitology 132, 581\u2013594 (2006).","journal-title":"Parasitology"},{"key":"67514_CR9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1128\/AAC.00173-08","volume":"52","author":"P Martins-Leite","year":"2008","unstructured":"Martins-Leite, P. et al. Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni. Antimicrob. Agents Chemother. 52, 2780\u20132786 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67514_CR10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1574-695X.2009.00640.x","volume":"58","author":"SA Rahoud","year":"2010","unstructured":"Rahoud, S. A. et al. Factors controlling the effect of praziquantel on liver fibrosis in Schistosoma mansoni-infected patients. FEMS Immunol. Med. Microbiol. 58, 106\u2013112 (2010).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"67514_CR11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.12659\/MSM.909320","volume":"24","author":"X Tang","year":"2018","unstructured":"Tang, X. et al. A polysaccharide from amusium pleuronectes combined with praziquantel treatment ameliorates hepatic fibrosis in schistosoma japonicum-infected mice. Med. Sci. Monit. 24, 1597\u20131603 (2018).","journal-title":"Med. Sci. Monit."},{"key":"67514_CR12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijid.2016.10.001","volume":"54","author":"DU Olveda","year":"2017","unstructured":"Olveda, D. U. et al. Biennial versus annual treatment for schistosomiasis and its impact on liver morbidity. Int. J. Infect. Dis. 54, 145\u2013149 (2017).","journal-title":"Int. J. Infect. Dis."},{"key":"67514_CR13","first-page":"241","volume":"29","author":"L Hong-Bao","year":"2016","unstructured":"Hong-Bao, L. & Ming, S. Efficacy of repeated application of praziquantel in treatment of hepatic fibrosis due to schistosomiasis. Zhongguo Xue. Xi. Chong. Bing. Fang Zhi. Za Zhi. 29, 241\u2013242 (2016).","journal-title":"Zhongguo Xue. Xi. Chong. Bing. Fang Zhi. Za Zhi."},{"key":"67514_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1164\/rccm.201101-0146OC","volume":"184","author":"A Crosby","year":"2011","unstructured":"Crosby, A. et al. Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am. J. Respir. Crit Care Med. 184, 467\u2013473 (2011).","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"67514_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0035-9203(98)91090-2","volume":"92","author":"P Boisier","year":"1998","unstructured":"Boisier, P. et al. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Trans. R. Soc. Trop. Med. Hyg. 92, 451\u2013453 (1998).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"67514_CR16","first-page":"797","volume":"110","author":"W Cai","year":"1997","unstructured":"Cai, W. et al. Changes of ultrasonography and two serum biochemical indices for hepatic fibrosis in schistosomiasis japonica patients one year after praziquantel treatment. Chin Med. J. (Engl.) 110, 797\u2013800 (1997).","journal-title":"Chin Med. J. (Engl.)"},{"issue":"Pt 4","key":"67514_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S0031182000067743","volume":"107","author":"TF Kresina","year":"1993","unstructured":"Kresina, T. F., He, Q., Degli, E. S. & Zern, M. A. Hepatic fibrosis and gene expression changes induced by praziquantel treatment during immune modulation of Schistosoma japonicum infection. Parasitology 107(Pt 4), 397\u2013404 (1993).","journal-title":"Parasitology"},{"key":"67514_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4269\/ajtmh.1992.46.409","volume":"46","author":"E Doehring-Schwerdtfeger","year":"1992","unstructured":"Doehring-Schwerdtfeger, E. et al. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Am. J. Trop. Med. Hyg. 46, 409\u2013415 (1992).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-4800(88)90029-9","volume":"49","author":"NM el-Badrawy","year":"1988","unstructured":"el-Badrawy, N. M. et al. Effect of praziquantel on hepatic fibrosis in experimental Schistosomiasis mansoni. Exp. Mol. Pathol. 49, 151\u2013160 (1988).","journal-title":"Exp. Mol. Pathol."},{"key":"67514_CR20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(88)90424-2","volume":"2","author":"MA Homeida","year":"1988","unstructured":"Homeida, M. A. et al. Effect of antischistosomal chemotherapy on prevalence of Symmers\u2019 periportal fibrosis in Sudanese villages. Lancet 2, 437\u2013440 (1988).","journal-title":"Lancet"},{"key":"67514_CR21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4269\/ajtmh.1985.34.314","volume":"34","author":"SH Morcos","year":"1985","unstructured":"Morcos, S. H. et al. Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis. Am. J. Trop. Med. Hyg. 34, 314\u2013321 (1985).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR22","first-page":"9162631","volume":"2016","author":"WM Wami","year":"2016","unstructured":"Wami, W. M. et al. Comparative assessment of health benefits of praziquantel treatment of urogenital schistosomiasis in preschool and primary school-aged children. Biomed. Res. Int. 2016, 9162631 (2016).","journal-title":"Biomed. Res. Int."},{"key":"67514_CR23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2149\/tmh.2014-S04","volume":"42","author":"DG Colley","year":"2014","unstructured":"Colley, D. G. Morbidity control of schistosomiasis by mass drug administration: how can we do it best and what will it take to move on to elimination?. Trop. Med. Health 42, 25\u201332 (2014).","journal-title":"Trop. Med. Health"},{"key":"67514_CR24","doi-asserted-by":"crossref","first-page":"e0181975","DOI":"10.1371\/journal.pone.0181975","volume":"12","author":"R Musuva","year":"2017","unstructured":"Musuva, R. et al. Change in children\u2019s school behavior after mass administration of praziquantel for Schistosoma mansoni infection in endemic areas of western Kenya: A pilot study using the Behavioral Assessment System for Children (BASC-2). PLoS ONE 12, e0181975 (2017).","journal-title":"PLoS ONE"},{"key":"67514_CR25","doi-asserted-by":"crossref","first-page":"e0005400","DOI":"10.1371\/journal.pntd.0005400","volume":"11","author":"B Barda","year":"2017","unstructured":"Barda, B., Coulibaly, J. T., Hatz, C. & Keiser, J. Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with Schistosoma haematobium and its evolution after praziquantel treatment: A randomized controlled trial. PLoS Negl. Trop. Dis. 11, e0005400 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"67514_CR26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41374-018-0154-0","volume":"99","author":"MCG Harvie","year":"2019","unstructured":"Harvie, M. C. G. et al.\u00a0Live imaging of collagen deposition during experimental hepatic schistosomiasis and recovery: a view on a dynamic process.\u00a0Lab Invest.\u00a099,\u00a0231\u2013243 (2019).","journal-title":"Lab Invest."},{"key":"67514_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpara.2009.06.008","volume":"40","author":"G Hrckova","year":"2010","unstructured":"Hrckova, G., Velebny, S. & Solar, P. Dynamics of hepatic stellate cells, collagen types I and III synthesis and gene expression of selected cytokines during hepatic fibrogenesis following Mesocestoides vogae (Cestoda) infection in mice. Int. J. Parasitol. 40, 163\u2013174 (2010).","journal-title":"Int. J. Parasitol."},{"key":"67514_CR28","doi-asserted-by":"crossref","first-page":"e0005372","DOI":"10.1371\/journal.pntd.0005372","volume":"11","author":"G Andrade","year":"2017","unstructured":"Andrade, G., Bertsch, D. J., Gazzinelli, A. & King, C. H. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis. PLoS. Negl. Trop. Dis. 11, e0005372 (2017).","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"67514_CR29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1017\/S0031182007002600","volume":"134","author":"F Angelucci","year":"2007","unstructured":"Angelucci, F. et al. The anti-schistosomal drug praziquantel is an adenosine antagonist. Parasitology 134, 1215\u20131221 (2007).","journal-title":"Parasitology"},{"key":"67514_CR30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.taap.2017.10.012","volume":"336","author":"RM Babes","year":"2017","unstructured":"Babes, R. M., Selescu, T., Domocos, D. & Babes, A. The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol. Appl. Pharmacol. 336, 55\u201365 (2017).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"67514_CR31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijpara.2014.12.008","volume":"45","author":"MS Ferreira","year":"2015","unstructured":"Ferreira, M. S. et al. Revealing praziquantel molecular targets using mass spectrometry imaging: an expeditious approach applied to Schistosoma mansoni. Int. J. Parasitol. 45, 385\u2013391 (2015).","journal-title":"Int. J. Parasitol."},{"key":"67514_CR32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.exppara.2006.09.017","volume":"115","author":"L Pica-Mattoccia","year":"2007","unstructured":"Pica-Mattoccia, L. et al. Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Exp. Parasitol. 115, 344\u2013351 (2007).","journal-title":"Exp. Parasitol."},{"key":"67514_CR33","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1111\/bph.14831","volume":"176","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Praziquantel ameliorates CCl4 -induced liver fibrosis in mice by inhibiting TGF-beta\/smad signalling via upregulating Smad7 in hepatic stellate cells. Br. J. Pharmacol. 176,\u00a04666\u20134680 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"67514_CR34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4269\/ajtmh.1991.45.360","volume":"45","author":"MA Homeida","year":"1991","unstructured":"Homeida, M. A., el Tom I., Nash, T. & Bennett, J. L. Association of the therapeutic activity of praziquantel with the reversal of Symmers\u2019 fibrosis induced by Schistosoma mansoni. Am. J. Trop. Med. Hyg. 45, 360\u2013365 (1991).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR35","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0021-9258(19)75686-5","volume":"262","author":"RA Pierce","year":"1987","unstructured":"Pierce, R. A. et al. Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. J. Biol. Chem. 262, 1652\u20131658 (1987).","journal-title":"J. Biol. Chem."},{"key":"67514_CR36","doi-asserted-by":"crossref","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","volume":"304","author":"M Zeisberg","year":"2013","unstructured":"Zeisberg, M. & Kalluri, R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am. J. Physiol. Cell Physiol 304, C216\u2013C225 (2013).","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"67514_CR37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00204-013-1078-5","volume":"87","author":"P Godoy","year":"2013","unstructured":"Godoy, P. et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87, 1315\u20131530 (2013).","journal-title":"Arch. Toxicol."},{"key":"67514_CR38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00204-012-0968-2","volume":"87","author":"S Messner","year":"2013","unstructured":"Messner, S., Agarkova, I., Moritz, W. & Kelm, J. M. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch. Toxicol. 87, 209\u2013213 (2013).","journal-title":"Arch. Toxicol."},{"key":"67514_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.111.187740","volume":"341","author":"D Xu","year":"2012","unstructured":"Xu, D. et al. RN486, a selective Bruton\u2019s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341, 90\u2013103 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"67514_CR40","first-page":"542","volume":"31","author":"G Webbe","year":"1981","unstructured":"Webbe, G., James, C., Nelson, G. S. & Sturrock, R. F. The effect of praziquantel on Schistosoma haematobium, S. japonicum and S. mansoni in primates. Arzneimittelforschung. 31, 542\u2013544 (1981).","journal-title":"Arzneimittelforschung."},{"key":"67514_CR41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1590\/S0037-86822007000500003","volume":"40","author":"R Ruiz-Guevara","year":"2007","unstructured":"Ruiz-Guevara, R. et al. Clinical and ultrasound findings before and after praziquantel treatment among Venezuelan schistosomiasis patients. Rev. Soc. Bras. Med. Trop. 40, 505\u2013511 (2007).","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"67514_CR42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4269\/ajtmh.1991.45.350","volume":"45","author":"H Ohmae","year":"1991","unstructured":"Ohmae, H. et al. Serologic and ultrasonographic parameters of praziquantel treatment of hepatic fibrosis in Schistosoma japonicum infection. Am. J. Trop. Med. Hyg. 45, 350\u2013359 (1991).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4269\/ajtmh.1992.46.99","volume":"46","author":"H Ohmae","year":"1992","unstructured":"Ohmae, H. et al. Improvement of ultrasonographic and serologic changes in Schistosoma japonicum-infected patients after treatment with praziquantel. Am. J. Trop. Med. Hyg. 46, 99\u2013104 (1992).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4269\/ajtmh.1991.44.444","volume":"44","author":"Q Mohamed-Ali","year":"1991","unstructured":"Mohamed-Ali, Q. et al. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. Am. J. Trop. Med. Hyg. 44, 444\u2013451 (1991).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12906-018-2191-z","volume":"18","author":"DM Metwally","year":"2018","unstructured":"Metwally, D. M., Al-Olayan, E. M., Alanazi, M., Alzahrany, S. B. & Semlali, A. Antischistosomal and anti-inflammatory activity of garlic and allicin compared with that of praziquantel in vivo. BMC Complement Altern. Med. 18, 135 (2018).","journal-title":"BMC Complement Altern. Med."},{"key":"67514_CR46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0035-9203(02)90386-X","volume":"96","author":"YS Li","year":"2002","unstructured":"Li, Y. S. et al. Five-year impact of repeated praziquantel treatment on subclinical morbidity due to Schistosoma japonicum in China. Trans. R. Soc. Trop. Med. Hyg. 96, 438\u2013443 (2002).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"67514_CR47","doi-asserted-by":"crossref","first-page":"e20247","DOI":"10.1371\/journal.pone.0020247","volume":"6","author":"YJ Liang","year":"2011","unstructured":"Liang, Y. J. et al. New insight into the antifibrotic effects of praziquantel on mice in infection with Schistosoma japonicum. PLoS ONE 6, e20247 (2011).","journal-title":"PLoS ONE"},{"key":"67514_CR48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijid.2017.10.023","volume":"66","author":"MT Inobaya","year":"2018","unstructured":"Inobaya, M. T. et al. Mass drug administration and the sustainable control of schistosomiasis: Community health workers are vital for global elimination efforts. Int. J. Infect. Dis. 66, 14\u201321 (2018).","journal-title":"Int. J. Infect. Dis."},{"key":"67514_CR49","first-page":"290","volume":"14","author":"N Hutradilok","year":"1983","unstructured":"Hutradilok, N., Ruenwongsa, P., Thamavit, W. & Upatham, E. S. Liver collagen in Opisthorchis viverrini infected hamsters following praziquantel treatment. Southeast Asian J. Trop. Med. Public Health 14, 290\u2013293 (1983).","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"67514_CR50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-3305-5-9","volume":"5","author":"NM El-Lakkany","year":"2012","unstructured":"El-Lakkany, N. M. et al. Anti-inflammatory\/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit. Vectors 5, 9 (2012).","journal-title":"Parasit. Vectors"},{"key":"67514_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nano.2015.10.005","volume":"12","author":"L Charoensuk","year":"2016","unstructured":"Charoensuk, L. et al. Nanoencapsulated curcumin and praziquantel treatment reduces periductal fibrosis and attenuates bile canalicular abnormalities in Opisthorchis viverrini-infected hamsters. Nanomedicine 12, 21\u201332 (2016).","journal-title":"Nanomedicine"},{"key":"67514_CR52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4269\/ajtmh.2008.78.228","volume":"78","author":"N Berhe","year":"2008","unstructured":"Berhe, N., Myrvang, B. & Gundersen, S. G. Reversibility of schistosomal periportal thickening\/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia. Am. J. Trop. Med. Hyg. 78, 228\u2013234 (2008).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exppara.2017.10.005","volume":"183","author":"NF Abd El-Aal","year":"2017","unstructured":"Abd El-Aal, N. F., Hamza, R. S. & Harb, O. Paeoniflorin targets apoptosis and ameliorates fibrosis in murine schistosomiasis mansoni: A novel insight. Exp. Parasitol. 183, 23\u201332 (2017).","journal-title":"Exp. Parasitol."},{"key":"67514_CR54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1017\/S0022149X18000317","volume":"93","author":"EVN Beshay","year":"2019","unstructured":"Beshay, E. V. N., Rady, A. A., Afifi, A. F. & Mohamed, A. H. Schistosomicidal, antifibrotic and antioxidant effects of Cucurbita pepo L. seed oil and praziquantel combined treatment for Schistosoma mansoni infection in a mouse model. J. Helminthol. 93, 286\u2013294 (2019).","journal-title":"J. Helminthol."},{"key":"67514_CR55","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4269\/ajtmh.1989.40.620","volume":"40","author":"AW Cheever","year":"1989","unstructured":"Cheever, A. W. & Deb, S. Persistence of hepatic fibrosis and tissue eggs following treatment of Schistosoma japonicum infected mice. Am. J. Trop. Med. Hyg. 40, 620\u2013628 (1989).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.exppara.2011.06.015","volume":"129","author":"N El-Lakkany","year":"2011","unstructured":"El-Lakkany, N., el-Din, S. S. & Ebeid, F. The use of pentoxifylline as adjuvant therapy with praziquantel downregulates profibrogenic cytokines, collagen deposition and oxidative stress in experimental schistosomiasis mansoni. Exp. Parasitol. 129, 152\u2013157 (2011).","journal-title":"Exp. Parasitol."},{"key":"67514_CR57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopha.2017.09.136","volume":"96","author":"A Elmasry","year":"2017","unstructured":"Elmasry, A., Aladeeb, N. M., Elkaref, A. & Aboulfotouh, N. Simvastatin exerts antifibrotic effect and potentiates the antischistosomal effects of praziquantel in a murine model: Role of IL10. Biomed. Pharmacother. 96, 215\u2013221 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"67514_CR58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fcimb.2017.00443","volume":"7","author":"YQ Li","year":"2017","unstructured":"Li, Y. Q. et al. Corilagin counteracts IL-13Ralpha1 signaling pathway in macrophages to mitigate schistosome egg-induced hepatic fibrosis. Front Cell Infect. Microbiol. 7, 443 (2017).","journal-title":"Front Cell Infect. Microbiol."},{"key":"67514_CR59","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s00436-018-5972-x","volume":"117","author":"Z Ma","year":"2018","unstructured":"Ma, Z. et al. Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice. Parasitol. Res. 117, 2831\u20132839 (2018).","journal-title":"Parasitol. Res."},{"key":"67514_CR60","doi-asserted-by":"crossref","first-page":"e0005691","DOI":"10.1371\/journal.pntd.0005691","volume":"11","author":"MC Sanchez","year":"2017","unstructured":"Sanchez, M. C. et al. Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection. PLoS. Negl. Trop. Dis. 11, e0005691 (2017).","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"67514_CR61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exppara.2017.05.005","volume":"178","author":"SA Sharaf El-Deen","year":"2017","unstructured":"Sharaf El-Deen, S. A., Brakat, R. M. & Mohamed, A. S. E. D. Artichoke leaf extract protects liver of Schistosoma mansoni infected mice through modulation of hepatic stellate cells recruitment. Exp. Parasitol. 178, 51\u201359 (2017).","journal-title":"Exp. Parasitol."},{"key":"67514_CR62","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.0019-2805.2004.01817.x","volume":"111","author":"KP Singh","year":"2004","unstructured":"Singh, K. P., Gerard, H. C., Hudson, A. P. & Boros, D. L. Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. Immunology 111, 343\u2013352 (2004).","journal-title":"Immunology"},{"key":"67514_CR63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.1840100116","volume":"10","author":"H Emonard","year":"1989","unstructured":"Emonard, H. & Grimaud, J. A. Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. Hepatology 10, 77\u201383 (1989).","journal-title":"Hepatology"},{"key":"67514_CR64","doi-asserted-by":"crossref","first-page":"752","DOI":"10.4269\/ajtmh.1992.46.752","volume":"46","author":"AW Cheever","year":"1992","unstructured":"Cheever, A. W., Macedonia, J. G., Deb, S., Cheever, E. A. & Mosimann, J. E. Persistence of eggs and hepatic fibrosis after treatment of Schistosoma mansoni-infected mice. Am. J. Trop. Med. Hyg. 46, 752\u2013758 (1992).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.1993.49.1","volume":"49","author":"ZA Andrade","year":"1993","unstructured":"Andrade, Z. A., Cox, T. M. & Cheever, A. M. Regression of hepatic lesions after treatment of Schistosoma mansoni or Schistosoma japonicum infection in mice: a comparative study. Am. J. Trop. Med. Hyg. 49, 1\u20139 (1993).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"67514_CR66","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nbt.2914","volume":"32","author":"NC Kleinstreuer","year":"2014","unstructured":"Kleinstreuer, N. C. et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 32, 583\u2013591 (2014).","journal-title":"Nat. Biotechnol."},{"key":"67514_CR67","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1128\/AAC.01936-13","volume":"58","author":"HA Mata-Santos","year":"2014","unstructured":"Mata-Santos, H. A. et al. Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis. Antimicrob. Agents Chemother. 58, 2076\u20132083 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67514_CR68","doi-asserted-by":"crossref","first-page":"e2005850","DOI":"10.1371\/journal.pbio.2005850","volume":"16","author":"AN Abdel","year":"2018","unstructured":"Abdel, A. N., Nono, J. K., Mpotje, T. & Brombacher, F. The Foxp3+ regulatory T-cell population requires IL-4Ralpha signaling to control inflammation during helminth infections. PLoS. Biol. 16, e2005850 (2018).","journal-title":"PLoS. Biol."},{"key":"67514_CR69","doi-asserted-by":"crossref","first-page":"e0005861","DOI":"10.1371\/journal.pntd.0005861","volume":"11","author":"JK Nono","year":"2017","unstructured":"Nono, J. K. et al. Host regulation of liver fibroproliferative pathology during experimental schistosomiasis via interleukin-4 receptor alpha. PLoS. Negl. Trop. Dis. 11, e0005861 (2017).","journal-title":"PLoS. Negl. Trop. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67514-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:06:14Z","timestamp":1670331974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67514-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67514"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67514-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TS is an employee of Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany. DX, KF and GV are employees of EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany. Merck KGaA was involved in the conceptualization, design, analysis of collected data, decision to publish, and preparation of the manuscript. All the remaining authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10638"}}